Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Sax you mention some news about MATINS in the coming weeks, is that relating to an FDA meeting? Or some other submission? Just a little thing to add, FDA type B (end of phase) meetings take place around 70 days after request. So if it was end of December, expect the meeting early March. So hopefully something exciting by the end of March would come from MATINS.
As a little note Sax, in my past experience, trial sponsors tend to get the trial entered into clinicaltrials.gov around the time as regulatory submission. It also takes around 30 days for the NIH to review any clinicaltrials.gov submissions. So in theory it could've been submitted and just be in the review period, meaning Q1 could still be feasible.
Sax's positive spin makes me feel a little better about this. One would hope that this is the last placing prior to a big breakthrough deal.
As Sax says though, adding this cash on top of the current balance is interesting and shows some good sign for the confidence in development. Perhaps this funding is more for the upcoming combination trial that is being discussed (referred to as BEXCOMBO on Faron's website). This would add even more partnership possibilities I suppose, which could be what they are banking on.
It's a good point quesera, I've said it before but I think the way they will proceed is to partner for a set indication, perhaps AML. This partnership could then fund the studies for other indications up to the point of end of phase 2.
From my work in pharma this makes the most sense, but who knows what is planned!
I didn't notice if this had been posted but it popped up on my feed today. Traumakine has been featured in LabBiotech regarding its potential role in multi-organ dysfunction, especially in-field applications.
It's an interesting read with a very interesting potential pathway to market:
https://www.labiotech.eu/trends-news/faron-pharmaceuticals-traumakine-data-militaty/
Question for those of you that may have been around the block before - what is the likelihood that Faron sells Bex for a certain cancer type (e.g. if leukemia does well, a company buying just the rights to AML)? I don't think that's a common strategy, but in this case where Faron seems to think it works for so many indications it seems like that could be a way for them to fund some of the next steps?
Covgaz it is weird and quite sad that you seem to enjoy that nobody cares about your opinions here. You're trolling on an investment forum that you have posted over a thousand times on, surely you have better things to do with your life?
It raises the question to me, I wonder what Farons buyout figure would be from your likes of AZ, Lilly or Novartis? I guess similar to Teneotwo it could vary based on milestones but Faron may just want a full purchase rather than partnership to mitigate some risk
Covgaz why do you spend so much time just talking about how disappointing Faron are? I don't understand the point or why. The share price is disappointing everyone can see that. Your depressing negativity to literally any post here is pointless for everyone.
Donald - Thanks for the insight and not being too defensive.
Almost similar to you, I have worked in the drug development industry my entire career, so of course invest. Based on my education and experience a small pharma like Faron would achieve best value for the shareholders by keeping hold of their molecule for as long as possible - on the assumption that their science is right. Of course if Clevegen, Traumakine or their third molecule do not show the hoped for clinical efficacy then it would've been better to partner/sell early.
To me, by funding their 4 Clevegen clinical trials, all for different indications, then they are putting themselves in the best position to get a real partner in a couple of years, if the data is preferable.
I'll be honest I'm not sure if the current Faron 'science first' approach is the right one to get the most value for us as shareholders, but I do expect that we will see a windfall either in the form of a huge breakthrough, or acquisition over the next few years.
I mainly just lurk here to see the general opinion and don't post, but Donald, can you please explain why you are still here? You obviously do not have a long term positive vision for faron, you seem to have a grudge against Markku based on his previous venture, so literally why are you here?
I'm not even attacking, just curious.